Expressing the sense of Congress that the Food and Drug Administration's (FDA) new policy restricting women's access to medications containing estriol does not serve the public interest.
The source supplies the latest action, but no lifecycle stage.
Latest action (7 May 2008): Referred to the Subcommittee on Health.
What this bill does
This resolution, H.Con.Res. 342, would express Congress's view that a new policy by the Food and Drug Administration (FDA) restricting women's access to medications with estriol is not in the public interest. The resolution states that the FDA will no longer permit pharmacists to prepare compounded medications containing estriol with a doctor's prescription. This change, according to the resolution, has led insurers to deny reimbursement for these compounded medications.
The resolution argues that physicians are best positioned to decide appropriate medications for their patients and that the FDA should respect the physician-patient relationship. It specifically calls for the FDA to reverse its policy that limits access to compounded estriol medications prescribed by physicians. The bill is a concurrent resolution, meaning it expresses the sentiment of both the House of Representatives and the Senate.
Introduced in May 2008, this bill was referred to a subcommittee of the House Committee on Energy and Commerce. As a concurrent resolution, it does not require the President's signature to become law. If passed by both houses of Congress, it would represent Congress's stated opinion on the matter, but it would not have the force of law.
Plain-English summary generated by Bill100 AI from the official record. Always verify against the source below.
Official summary
Calls for the Food and Drug Administration (FDA) to reverse its policy that aims to eliminate patient access to compounded medications containing estriol prescribed by physicians.
Timeline
7 May 2008
Referred to the Subcommittee on Health.
Common questions
- What does H.Con.Res. 342 do?
- This resolution, H.Con.Res. 342, would express Congress's view that a new policy by the Food and Drug Administration (FDA) restricting women's access to medications with estriol is not in the public interest. The resolution states that the FDA will no longer permit pharmacists to prepare compounded medications containing estriol with a doctor's prescription. This change, according to the resolution, has led insurers to deny reimbursement for these compounded medications. The resolution argues that physicians are best positioned to decide appropriate medications for their patients and that the FDA should respect the physician-patient relationship. It specifically calls for the FDA to reverse its policy that limits access to compounded estriol medications prescribed by physicians. The bill is a concurrent resolution, meaning it expresses the sentiment of both the House of Representatives and the Senate. Introduced in May 2008, this bill was referred to a subcommittee of the House Committee on Energy and Commerce. As a concurrent resolution, it does not require the President's signature to become law. If passed by both houses of Congress, it would represent Congress's stated opinion on the matter, but it would not have the force of law.
- Has H.Con.Res. 342 become law?
- The source does not supply a confirmed lifecycle stage for H.Con.Res. 342. Check the latest action and official source below.
- Who sponsored H.Con.Res. 342?
- H.Con.Res. 342 was sponsored by Rep. Ross, Mike [D-AR-4] (D-AR), with 58 cosponsors.
- What's the latest action on H.Con.Res. 342?
- Referred to the Subcommittee on Health. (7 May 2008).
Related bills in Health
Choices for Increased Mobility Act of 2026
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Access to Medical Supplies Act
Lower Premiums, Faster Payments Act
Bill100 mirrors the public U.S. legislative record from Congress.gov and GovTrack and adds plain-English AI summaries. It is an information tool, not legal, compliance or lobbying advice, and it is not affiliated with the U.S. Congress or any government agency. AI summaries can simplify or omit detail — every bill links to the official source; verify there before you rely on it.